ArticleCNS neuroscience & therapeutics2026
MBOAT1 Promotes Glioma Progression Through Enhancing Ferroptosis Resistance and Immunosuppressive Microenvironment.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular Effects of Indocyanine Green-Photodynamic Therapy on Programmed Cell Death Pathways in T98G and U-118MG Glioblastoma Cells-An RT-qPCR Study.Current issues in molecular biology · 2026Article
- Predicting diagnostic gene biomarkers in allergic asthma.Medicine · 2026Article
- MBOAT1 Promotes Glioma Progression Through Enhancing Ferroptosis Resistance and Immunosuppressive Microenvironment.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEmerging evidence indicates that ferroptosis characterized by lipid peroxidation is becoming a promising therapeutic strategy in glioma. However, the role of the MBOAT family, key regulators of membrane phospholipids remodeling in ferroptosis, remains unexplored in glioma.
methodsWe systematically analyzed the expression and clinical significance of MBOAT1 in glioma using TCGA, CGGA, GEO, and GTEx databases. Functional mechanisms were investigated through enrichment, single-cell RNA sequencing, and immune infiltration analyses. We experimentally validated the oncogenic role of MBOAT1 in GBM through both in vivo and in vitro experiments.
resultsMBOAT1 expression was elevated in glioma and correlated with increased grades and poor patient prognosis. Cox regression analysis identified MBOAT1 as an independent prognostic factor. Functional enrichment analysis and single cell RNA-seq analysis revealed that MBOAT1 is associated with enhanced ferroptosis resistance. Furthermore, the immune infiltration analysis and cell communication analysis suggested that MBOAT1 promotes an immunosuppressive microenvironment. Experiments confirmed that overexpression of MBOAT1 promoted GBM cell proliferation, migration, invasion, and ferroptosis resistance, while its knockdown had the opposite effect.
conclusionOur findings suggest that MBOAT1 promotes glioma progression by mediating ferroptosis resistance and is related to an immunosuppressive microenvironment, highlighting its potential as an independent prognostic biomarker and a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.